Mitral Valve Prolapse Causes Symptoms in Many and Regurgitation in Some. There Is Also a Rare Sudden Death Phenotype.

2. What It Is

Mitral valve prolapse (MVP) is defined echocardiographically as the displacement of one or both mitral valve leaflets 2 mm or more above the mitral annular plane into the left atrium during systole, in the parasternal long-axis view 5 / Solid . The leaflets themselves may be thickened (myxomatous MVP) or relatively thin (fibroelastic deficiency MVP).

MVP is the most common primary valve abnormality in the Western world. The Framingham Heart Study found an echocardiographic prevalence of approximately 2.4% in the general population, with equal distribution in men and women 5 / Solid . Older studies had reported prevalences of 5-10%, inflated by older diagnostic criteria that included lateral and apical views with foreshortened annular planes.

Pathological subtypes

Myxomatous MVP (Barlow’s disease): Extensive myxomatous degeneration of all segments of both leaflets, often with annular dilation. The leaflets are thick, redundant, and “billowing.” This is a diffuse process of the entire mitral apparatus. Typically presents in older patients with progressive MR.

Fibroelastic deficiency MVP: The leaflets are structurally thin and deficient in collagen and elastin, with focal prolapse (usually the P2 segment). A single chordal rupture causes the acute flail leaflet seen in some MVP patients. Typically presents in older patients (60s-70s) with acute MR from a chord that ruptures.

Classic vs non-classic MVP: Classic MVP: leaflet thickness above 5 mm, or superior displacement of 5 mm or above, or both. Non-classic MVP: leaflet thickness 5 mm or below with displacement 2-5 mm. Non-classic MVP is the more common, lower-severity form.

3. The Mechanism

The mitral valve apparatus

The mitral valve is a complex apparatus: two leaflets (anterior, posterior), two papillary muscles (anterolateral and posteromedial), chordae tendineae connecting papillary muscles to leaflet free edges, and the fibrous mitral annulus. The posterior leaflet is divided into three scallops: P1 (lateral), P2 (central), P3 (medial). Similarly, A1, A2, A3 for the anterior leaflet. The P2 segment prolapse is the most common anatomical finding.

Why MVP causes prolapse

In myxomatous MVP, the glycosaminoglycan accumulation in the valve leaflet substance disrupts the layered architecture of fibrosa, spongiosa, and atrialis, replacing normal collagen with mucopolysaccharide. The leaflet becomes thickened, floppy, and unable to resist the systolic LV pressure that would otherwise keep it in the LV cavity. The mitral annulus also enlarges in severe myxomatous disease. The result: the leaflet billows upward into the LA in mid-to-late systole.

In fibroelastic deficiency MVP, the chordae are thin and fragile. Spontaneous chordal elongation causes progressive leaflet prolapse; eventual rupture causes acute severe MR.

Arrhythmic MVP: the MVP-SCD syndrome

This is the most clinically critical mechanistic understanding in MVP biology. In 2015, Basso C, et al. (JACC 2015; 10.1016/j.jacc.2015.05.067) described a specific autopsy-confirmed MVP syndrome in young patients with unexplained sudden cardiac death: bileaflet MVP with complex mitral annulus disjunction (MAD), redundant leaflets, and late gadolinium enhancement (fibrosis) in the inferolateral papillary muscle and adjacent LV wall on pre-mortem CMR 5 / Solid .

Mitral annulus disjunction (MAD) is a separation between the posterior mitral annular attachment and the LV myocardium, visible as a gap on echocardiography or CMR. The abnormal motion of the posterior wall in MAD produces mechanical stretch of the papillary muscles and adjacent myocardium during systole. This mechanical stretch-induced fibrosis creates the substrate for ventricular arrhythmias.

The Perazzolo Marra C, et al., Circulation 2016 paper (10.1161/CIRCULATIONAHA.115.017160) confirmed this in a prospective series: MVP patients with LGE on CMR had a significantly higher prevalence of complex ventricular arrhythmias on ambulatory ECG compared to MVP patients without LGE 5 / Solid . The specific arrhythmia: premature ventricular complexes with a bigeminy or trigeminy pattern, originating from the papillary muscle-basal LV region. These can trigger VF.

4. How We Diagnose

Auscultation

The classic auscultatory finding of MVP: a mid-systolic click followed by a late systolic murmur at the apex. The click represents the sudden tensing of prolapsing leaflets at maximum displacement; the murmur reflects the resulting MR. Dynamic auscultation is essential:

• Standing or Valsalva (reduces LV volume): the click moves earlier in systole (moves toward S1); the murmur lengthens
• Squatting or lying down (increases LV volume): the click moves later in systole (moves toward S2); the murmur shortens
• Handgrip (increases afterload): click moves later, murmur shortens

These dynamic changes confirm MVP and distinguish it from other valve pathologies (AS, HCM, innocent flow murmur).

Some patients with MVP have no murmur (non-MR prolapse) and the diagnosis is made echocardiographically, sometimes incidentally.

Echocardiography

The primary diagnostic modality. Requirements for MVP diagnosis:

• Parasternal long-axis view: leaflet displacement above 2 mm above the mitral annular plane during systole
• Assessment of leaflet thickness (classic vs non-classic), affected segments, degree of MR, and annular dimension
• Assessment for mitral annulus disjunction (MAD): a separation visible between the posterior mitral annular hinge point and the adjacent LV posterior wall

Cardiac MRI

CMR with late gadolinium enhancement is the most sensitive tool for identifying fibrosis in the papillary muscles and basal inferolateral LV wall in MVP-SCD patients. In the Basso and Perazzolo Marra series, LGE was present in MVP patients with complex VAs at a high rate and was absent or minimal in MVP patients without arrhythmic risk. LGE above a certain threshold correlates with arrhythmic events.

CMR is not routinely performed in all MVP patients, but it is indicated in:

• MVP with complex VA (non-sustained VT, frequent PVCs, particularly papillary-origin PVCs)
• MVP with syncope of unclear mechanism
• MVP with family history of unexplained sudden death
• Bileaflet MVP with MAD on echocardiogram

Ambulatory ECG monitoring

For MVP patients with palpitations, syncope, or arrhythmia risk factors, prolonged ambulatory monitoring is appropriate: 30-day event monitor (Zio Patch, iRhythm; or similar) captures PVC burden, PVC morphology (papillary muscle origin = left bundle branch block morphology), non-sustained VT episodes, and nocturnal arrhythmia. Apple Watch ECG App (FDA 510(k) cleared) can identify AF but cannot quantify PVC burden; it is not a substitute for formal ambulatory monitoring in this context.

5. The Evidence

Natural history: the Grigioni and Essayagh data

Grigioni F, et al., Circulation 1999 and subsequent series: In patients with MVP and significant MR, the natural history depends on MR severity, LV remodeling, and the development of symptoms. Patients with moderate-to-severe MR from MVP had annual rates of developing symptoms or LV dysfunction of approximately 6-10% per year 5 / Solid .

Essayagh B, et al., JACC 2021 (10.1016/j.jacc.2021.08.037): The Olmsted County MVP natural history study followed 833 patients. Among patients with moderate-to-severe or severe MR, 5-year mortality was significantly higher than age-matched controls. But even in patients with mild MR, MVP with bileaflet prolapse or annular disjunction was associated with higher rates of ventricular arrhythmia and adverse events 5 / Solid . This validated the arrhythmic MVP phenotype in a population-based cohort rather than just referral series.

MVP-SCD: the Basso 2015 autopsy series

Basso C, et al., JACC 2015 enrolled 43 young patients who died suddenly with autopsy-confirmed MVP, matched to living MVP controls 5 / Solid . Key findings:

• Bileaflet MVP was present in 93% of SCD cases vs 67% of controls
• Mitral annulus disjunction was present in 95% of SCD cases vs 70% of controls
• Myxomatous fibrosis in the basal inferior LV was present in 79% of SCD cases vs 24% of controls
• 73% of SCD cases were young women

The SCD from MVP in young women: this is an important and underappreciated demographic. The population-level SCD attributable to MVP is not large in absolute numbers, but in young women, MVP is a leading cause of unexplained sudden death, and the cases that reach autopsy frequently show the MAD-LGE phenotype.

Arrhythmic MVP risk markers: consensus criteria

Based on the Basso, Perazzolo Marra, and Essayagh data, the following criteria collectively define arrhythmic MVP risk:

• Bileaflet MVP
• Mitral annulus disjunction (MAD)
• Myxomatous features (leaflet thickness above 5 mm)
• Late gadolinium enhancement on CMR in basal inferior LV or papillary muscles
• Complex ventricular arrhythmias on ambulatory monitoring (papillary muscle-origin PVCs, frequent PVCs above 10,000/day, NSVT)
• Female sex
• Unexplained syncope

A patient with three or more of these features warrants electrophysiology consultation and consideration of ICD implant if non-sustained VT or resuscitated VF is documented.

Catheter ablation for MVP-related VT/VF

For arrhythmic MVP patients with recurrent VF or symptomatic VT triggered by papillary muscle PVCs, catheter ablation targeting the papillary muscle trigger (anterolateral or posteromedial papillary muscle) has shown success in eliminating the triggering PVCs and reducing VF recurrence 4 / Promising . This is a specialized procedure available at EP centers with high-volume papillary muscle ablation experience (Northwestern Memorial, Chicago; University of Chicago).

6. The Patient Experience

The MVP patient falls into two groups with very different experiences.

The “common MVP” patient is told at an annual exam or an echo ordered for palpitations that they have MVP. The cardiologist’s words are reassuring: “very common,” “most people never have a problem,” “come back if symptoms change.” The patient lives with a diagnosis that sounds serious but is described as benign. Palpitations are attributed to anxiety. The click is heard at annual physicals. The echocardiogram is repeated every 3-5 years, showing stable findings. This patient does well.

The arrhythmic MVP patient is often young, female, and has palpitations that are dismissed. The syncope is called vasovagal. The echocardiogram shows “MVP with mild MR, stable.” The CMR has never been ordered. The ambulatory ECG shows 18,000 PVCs per day and two runs of NSVT at night, but no one ordered it. The family history of early cardiac death is noted as “not cardiac” because no one investigated it.

The distinction between these two patients is not made by asking “do you have symptoms?” It is made by a systematic evaluation of MVP morphology (bileaflet? MAD?), CMR (LGE?), ambulatory monitoring (VA burden?), and family history review.

The nurse from the western suburbs: her brother’s “cardiac arrhythmia, undetermined” may have been arrhythmic MVP. Her bileaflet MVP and a 30-day monitor showing 22,000 PVCs and three runs of NSVT are the data that now trigger electrophysiology referral, CMR, and family screening. This is the conversation she should have had at 19.

7. Decisions and Trade-Offs

Who needs CMR?

CMR with LGE is not standard care for all MVP patients. The cost (approximately $800-1,200 per study), access barriers, and the low absolute risk of SCD in the general MVP population (approximately 1-2 per 10,000 MVP patients per year) argue against universal CMR. The targeted approach:

• All MVP patients with complex VA (NSVT, papillary-origin PVCs)
• MVP with syncope of unclear mechanism
• MVP with any combination of bileaflet morphology + MAD + symptoms
• MVP with family history of unexplained SCD

ICD in arrhythmic MVP: no randomized trial

There is no RCT for ICD implantation in arrhythmic MVP, because the population is small and the endpoint (SCD) is infrequent enough that an adequately powered trial would require very long follow-up. The decision is based on consensus: documented VF or resuscitated arrest in a young MVP patient with LGE and bileaflet morphology is a clear indication for secondary prevention ICD. Primary prevention ICD in an asymptomatic arrhythmic MVP patient with LGE, NSVT, and MAD but no documented VF/VT is a shared decision-making discussion without a guideline threshold.

Mitral valve surgery in MVP-SCD

There is observational evidence that mitral valve repair in arrhythmic MVP patients reduces the mechanical trigger (MAD and annular motion) and may reduce arrhythmic events, independent of the MR reduction 3 / Early . Valve repair in an arrhythmic MVP patient with severe MR addresses both indications simultaneously. Whether valve repair in an arrhythmic MVP patient with only mild or moderate MR reduces SCD risk is not established.

The athlete with MVP

Competitive sports in MVP: the 2020 ACC/AHA HCM guidelines do not cover MVP specifically. The presence of arrhythmic risk markers (LGE, bileaflet + MAD, complex VA) shifts the calculation. Athletes with arrhythmic MVP should be evaluated by a sports cardiologist before return to competition. Athletes with classic non-arrhythmic MVP and no MR above mild can generally participate.

Pregnancy and MVP

MVP in pregnancy: for the large majority of patients with non-arrhythmic MVP and no significant MR, pregnancy is well-tolerated. The physiological decrease in systemic vascular resistance during pregnancy may actually reduce the degree of MR. Serial echocardiography during pregnancy is not routinely required for mild or non-hemodynamically significant MVP.

For patients with moderate or severe MR from MVP, pregnancy is higher risk: the volume loading of pregnancy and the postpartum fluid shifts can precipitate or worsen pulmonary congestion. Pre-conception cardiology evaluation with a clear severity baseline (LVESD, EF, MR grade) is appropriate. Some patients with severe MR and severe symptoms should be counseled about valve repair before attempting pregnancy.

For arrhythmic MVP patients on antiarrhythmic therapy: beta-blockers are generally compatible with pregnancy. Quinidine and flecainide carry risk data that require case-by-case review with a cardiologist and maternal-fetal medicine specialist.

Clinical Synthesis

Mitral valve prolapse is the valve disease where the greatest risk of clinical harm comes from the phrase “it’s benign, don’t worry.” That phrase is accurate for the majority of patients. It is potentially fatal for the subgroup with arrhythmic MVP syndrome.

A structured cardiovascular assessment does not dismiss any MVP diagnosis with a generic reassurance. The standard Audit protocol for MVP:

1. Echocardiographic morphology review: bileaflet vs isolated posterior? MAD present?
2. Ambulatory ECG monitoring if palpitations, syncope, or family history of unexplained SCD
3. CMR if complex VA or bileaflet + MAD
4. Family history review for unexplained SCD in first-degree relatives under 40
5. Document and communicate the specific risk level clearly to the patient

Structured remote monitoring for MVP patients with significant MR (moderate or greater): serial echocardiography every 1-2 years per VALV-003 guidelines, with referral to experienced surgical centers when thresholds approach.

For arrhythmic MVP patients: electrophysiology consultation at Northwestern Memorial, University of Chicago, or Rush University Medical Center is the appropriate referral pathway in Illinois. For rural and downstate Illinois patients, Carle Foundation Hospital coordinates referral to Chicago EP programs for patients who need catheter ablation or ICD implantation for arrhythmic MVP.

The nurse from the western suburbs received her CMR last month. LGE was present in both papillary muscles. She is meeting with an electrophysiologist next week. The management plan will include a formal VT/VF risk assessment and a decision about ICD. Her MVP will be managed, not assumed benign.

Her brother’s death was not “undetermined.” His family now knows what to call it.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.